Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common monogenic kidney disease and the fourth cause of renal failure among adults, with close to $3.5 billion spent annually on the treatment of patients in the US alone. Yet there remain tremendous challenges in several facets of the disease, including the need for additional therapies to delay disease progression and identification of early disease specific biomarkers to assess disease severity, monitor disease progression and a treatment effect, from early stages of the disease. The findings resulting from this study will: 1) advance the understanding in the pathophysiology of ADPKD, 2) may identify novel biomarkers, and 3) point out additional mechanisms that could be target for therapeutic intervention.
|Effective start/end date||5/1/21 → 3/31/22|
- National Institute of Diabetes and Digestive and Kidney Diseases: $616,064.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.